Patent · US Active

Single variable domain antibodies against OX40L, constructs and therapeutic use

US8962807B2 · kind B2 · utility

24Cited by

1References

20Claims

0Family size

Assignee

Ablynx N.V. · BE

Inventors

Frank Kamiel Delphina Verdonck · Sint-Gillis-Waas, BE
Sigrid Cornelis · Gent, BE
Stephanie Staelens · Wevelgem, BE

Key dates

Filing date	Dec 14, 2010
Grant date	Feb 24, 2015
Priority date	—
Expiry date	Dec 14, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.